αž‘αžΈαž•αŸ’αžŸαžΆαžš
Prenetics Global Ltd
8.49$
αž€αŸ’αžšαŸ„αž™αž˜αŸ‰αŸ„αž„αŸ–
8.49$
(0.00%)0.00
αž”αžΆαž“αž”αž·αž‘αŸ– 27 αž˜αž·αžαž»αž“αžΆ, 4:02:00 PM αž˜αŸ‰αŸ„αž„β€‹αžŸαž€αž› -4 · USD · NASDAQ · αžŸαŸαž…αž€αŸ’αžŠαžΈαž”αŸ’αžšαž€αžΆαžŸαž˜αž·αž“αž‘αž‘αž½αž›αžαž»αžŸαžαŸ’αžšαžΌαžœ
αž—αžΆαž‚β€‹αž αŸŠαž»αž“αž˜αžΌαž›αž”αžαŸ’αžšαžŠαŸ‚αž›αž”αžΆαž“αž…αž»αŸ‡αž”αž‰αŸ’αž‡αžΈαž“αŸ… αž’αžΆαž˜αŸαžšαž·αž€
αž”αž·αž‘αž–αžΈαž˜αž»αž“
9.00$
αž…αž“αŸ’αž›αŸ„αŸ‡αžαŸ’αž„αŸƒαž“αŸαŸ‡
8.19$ - 9.00$
αž…αž“αŸ’αž›αŸ„αŸ‡αž˜αž½αž™αž†αŸ’αž“αžΆαŸ†αž…αž»αž„αž€αŸ’αžšαŸ„αž™
3.09$ - 11.99$
αžŠαžΎαž˜β€‹αž‘αž»αž“β€‹αž‘αžΈαž•αŸ’αžŸαžΆαžš
110.66Β αž›αžΆαž“ USD
αž‘αŸ†αž αŸ†αž‡αž½αž‰αžŠαžΌαžšαž˜αž’αŸ’αž™αž˜
73.91Β αž–αžΆαž“αŸ‹
αž’αž“αž»αž”αžΆαž P/E
-
αž‘αž·αž“αŸ’αž“αž•αž›β€‹αž—αžΆαž‚αž›αžΆαž—
-
αž€αžΆαžšαžŠαŸ„αŸ‡αžŠαžΌαžšαž…αž˜αŸ’αž”αž„
NASDAQ
αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž»
αžšαž”αžΆαž™αž€αžΆαžšαžŽαŸαž”αŸ’αžšαžΆαž€αŸ‹αž…αŸ†αžŽαžΌαž›
αž…αŸ†αžŽαžΌαž›
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’
(USD)αž˜αžΈαž“αžΆ 2025αž€αžΆαžšαž•αŸ’αž›αžΆαžŸαŸ‹αž”αŸ’αžŠαžΌαžšαžαžΆαž˜β€‹αž†αŸ’αž“αžΆαŸ†
αž…αŸ†αžŽαžΌαž›
17.31Β αž›αžΆαž“169.93%
αž…αŸ†αžŽαžΆαž™αž”αŸ’αžšαžαž·αž”αžαŸ’αžαž·αž€αžΆαžš
17.97Β αž›αžΆαž“38.89%
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’
-10.39Β αž›αžΆαž“-21.26%
αž”αŸ’αžšαžΆαž€αŸ‹αž…αŸ†αžŽαŸαž‰αžŸαž»αž‘αŸ’αž’
-60.0255.07%
β€‹αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’β€‹αž€αŸ’αž“αž»αž„αž˜αž½αž™αž—αžΆαž‚αž αŸŠαž»αž“
β€”β€”
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’αž˜αž»αž“αž€αžΆαžšαž”αŸ’αžšαžΆαž€αŸ‹ αž–αž“αŸ’αž’ αž€αžΆαžšαžšαŸ†αž›αžŸαŸ‹ αž“αž·αž„αž€αžΆαžšαž€αžΆαžαŸ‹αžšαŸ†αž›αžŸαŸ‹
-9.80Β αž›αžΆαž“-21.61%
αž’αžαŸ’αžšαžΆαž–αž“αŸ’αž’αžŠαŸ‚αž›αž˜αžΆαž“αž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–
0.58%β€”
αž‘αŸ’αžšαž–αŸ’αž™αžŸαžšαž»αž”
αž€αžΆαžšαž‘αž‘αž½αž›αžαž»αžŸαžαŸ’αžšαžΌαžœαžŸαžšαž»αž”
(USD)αž˜αžΈαž“αžΆ 2025αž€αžΆαžšαž•αŸ’αž›αžΆαžŸαŸ‹αž”αŸ’αžŠαžΌαžšαžαžΆαž˜β€‹αž†αŸ’αž“αžΆαŸ†
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹ αž“αž·αž„αž€αžΆαžšαžœαž·αž“αž·αž™αŸ„αž‚αžšαž™αŸˆαž–αŸαž›αžαŸ’αž›αžΈ
65.46Β αž›αžΆαž“-8.15%
αž‘αŸ’αžšαž–αŸ’αž™αžŸαžšαž»αž”
204.02Β αž›αžΆαž“-16.24%
αž€αžΆαžšαž‘αž‘αž½αž›αžαž»αžŸαžαŸ’αžšαžΌαžœαžŸαžšαž»αž”
42.90Β αž›αžΆαž“5.09%
αž˜αžΌαž›β€‹αž’αž“αžŸαžšαž»αž”
161.12Β αž›αžΆαž“β€”
αž—αžΆαž‚αž αŸŠαž»αž“β€‹αž˜αž·αž“β€‹αž‘αžΆαž“αŸ‹αž”αžΆαž“αž”αž„αŸ‹
13.00Β αž›αžΆαž“β€”
αžαž˜αŸ’αž›αŸƒαž’αŸ€αž”αž“αžΉαž„αžŸαŸ€αžœαž—αŸ…
0.73β€”
αž•αž›αž…αŸ†αžŽαŸαž‰αž›αžΎαž‘αŸ’αžšαž–αŸ’αž™
-12.73%β€”
αž•αž›αž…αŸ†αžŽαŸαž‰αž›αžΎαžŠαžΎαž˜αž‘αž»αž“
-15.48%β€”
αž€αžΆαžšαž”αŸ’αžšαŸ‚αž”αŸ’αžšαž½αž›β€‹αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αžŸαž»αž‘αŸ’αž’
(USD)αž˜αžΈαž“αžΆ 2025αž€αžΆαžšαž•αŸ’αž›αžΆαžŸαŸ‹αž”αŸ’αžŠαžΌαžšαžαžΆαž˜β€‹αž†αŸ’αž“αžΆαŸ†
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’
-10.39Β αž›αžΆαž“-21.26%
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž–αžΈαž”αŸ’αžšαžαž·αž”αžαŸ’αžαž·αž€αžΆαžš
β€”β€”
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž–αžΈαž€αžΆαžšαžœαž·αž“αž·αž™αŸ„αž‚
β€”β€”
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž–αžΈαž αž·αžšαž‰αŸ’αž‰β€‹αž”αŸ’αž”αž‘αžΆαž“
β€”β€”
αž€αžΆαžšαž”αŸ’αžšαŸ‚αž”αŸ’αžšαž½αž›β€‹αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αžŸαž»αž‘αŸ’αž’
β€”β€”
αž›αŸ†αž αžΌαžšαžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž‘αŸ†αž“αŸαžš
β€”β€”
αž’αŸ†αž–αžΈ
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
αž”αžΆαž“αž”αž„αŸ’αž€αžΎαžαž‘αžΎαž„
2014
αžαŸ†αž”αž“αŸ‹β€‹αž”αžŽαŸ’αžŠαžΆαž‰
αž”αž»αž‚αŸ’αž‚αž›αž·αž€
285
αžŸαŸ’αžœαŸ‚αž„αžšαž€β€‹αž…αŸ’αžšαžΎαž“αž‘αŸ€αž
αž’αŸ’αž“αž€αž’αžΆαž…αž…αžΆαž”αŸ‹αž’αžΆαžšαž˜αŸ’αž˜αžŽαŸαž›αžΎ
αž”αž‰αŸ’αž‡αžΈαž“αŸαŸ‡αžαŸ’αžšαžΌαžœαž”αžΆαž“αž”αž„αŸ’αž€αžΎαžαž‘αžΎαž„αž–αžΈαž€αžΆαžšαžŸαŸ’αžœαŸ‚αž„αžšαž€αžαŸ’αž˜αžΈαŸ— αž˜αžΌαž›αž”αžαŸ’αžšαžŠαŸ‚αž›αž”αžΆαž“αžαžΆαž˜αžŠαžΆαž“ αž“αž·αž„αžŸαž€αž˜αŸ’αž˜αž—αžΆαž–αž•αŸ’αžŸαŸαž„αž‘αŸ€αžαŸ” αžŸαŸ’αžœαŸ‚αž„αž™αž›αŸ‹αž”αž“αŸ’αžαŸ‚αž˜

αž‘αž·αž“αŸ’αž“αž“αŸαž™ αž“αž·αž„αž–αŸαžαŸŒαž˜αžΆαž“αž‘αžΆαŸ†αž„αž’αžŸαŸ‹αžαŸ’αžšαžΌαžœαž”αžΆαž“αž•αŸ’αžαž›αŸ‹αž‡αžΌαž“ β€œαžŠαžΌαž…αžŠαŸ‚αž›αž˜αžΆαž“β€ αžŸαž˜αŸ’αžšαžΆαž”αŸ‹αžαŸ‚αž‚αŸ„αž›αž”αŸ†αžŽαž„αž–αŸαžαŸŒαž˜αžΆαž“αž•αŸ’αž‘αžΆαž›αŸ‹αžαŸ’αž›αž½αž“αž”αŸ‰αž»αžŽαŸ’αžŽαŸ„αŸ‡ αž αžΎαž™αž˜αž·αž“αž˜αžΆαž“αž‚αŸ„αž›αž”αŸ†αžŽαž„αž•αŸ’αžŠαž›αŸ‹β€‹αž‡αžΆαžŠαŸ†αž”αžΌαž“αŸ’αž˜αžΆαž“αž•αŸ’αž“αŸ‚αž€αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž» αž¬αž€αŸαžŸαž˜αŸ’αžšαžΆαž”αŸ‹αž‚αŸ„αž›αž”αŸ†αžŽαž„αž–αžΆαžŽαž·αž‡αŸ’αž‡αž€αž˜αŸ’αž˜αž¬αž€αžΆαžšαžœαž·αž“αž·αž™αŸ„αž‚ αž–αž“αŸ’αž’ αž…αŸ’αž”αžΆαž”αŸ‹ αž‚αžŽαž“αŸαž™αŸ’αž™ αž¬αžŠαŸ†αž”αžΌαž“αŸ’αž˜αžΆαž“αž•αŸ’αžŸαŸαž„αž‘αŸ€αžαž‘αžΎαž™αŸ” Google αž˜αž·αž“αž˜αŸ‚αž“αž‡αžΆαž‘αžΈαž”αŸ’αžšαžΉαž€αŸ’αžŸαžΆαž•αŸ’αž“αŸ‚αž€αžœαž·αž“αž·αž™αŸ„αž‚ αž¬αž‘αžΈαž”αŸ’αžšαžΉαž€αŸ’αžŸαžΆαž•αŸ’αž“αŸ‚αž€αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž»αž‘αŸ αž“αž·αž„αž˜αž·αž“αž”αž‰αŸ’αž…αŸαž‰αž‘αžŸαŸ’αžŸαž“αŸˆ αž€αžΆαžšαžŽαŸ‚αž“αžΆαŸ† αž¬αž‚αŸ†αž“αž·αžαž™αŸ„αž”αž›αŸ‹αž–αžΆαž€αŸ‹αž–αŸαž“αŸ’αž’αž“αžΉαž„αž€αŸ’αžšαž»αž˜αž αŸŠαž»αž“αžŽαžΆαž˜αž½αž™αžŠαŸ‚αž›αž˜αžΆαž“αž€αŸ’αž“αž»αž„αž”αž‰αŸ’αž‡αžΈαž“αŸαŸ‡ αž¬αž˜αžΌαž›αž”αžαŸ’αžšαžŽαžΆαž˜αž½αž™αžŠαŸ‚αž›αž…αŸαž‰αžŠαŸ„αž™αž€αŸ’αžšαž»αž˜αž αŸŠαž»αž“αž‘αžΆαŸ†αž„αž“αŸ„αŸ‡αžŠαŸ‚αžšαŸ” αžŸαžΌαž˜αž–αž·αž‚αŸ’αžšαŸ„αŸ‡αž‡αžΆαž˜αž½αž™αžˆαŸ’αž˜αž½αž‰αž€αžŽαŸ’αžαžΆαž› αž¬αžαŸ†αžŽαžΆαž„αž•αŸ’αž“αŸ‚αž€αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž»αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€ αžŠαžΎαž˜αŸ’αž”αžΈαž•αŸ’αž‘αŸ€αž„αž•αŸ’αž‘αžΆαžαŸ‹αžαž˜αŸ’αž›αŸƒαž˜αž»αž“αž“αžΉαž„αž”αŸ’αžšαžαž·αž”αžαŸ’αžαž·αž€αžΆαžšαž‡αž½αž‰αžŠαžΌαžšαžŽαžΆαž˜αž½αž™αŸ” αžŸαŸ’αžœαŸ‚αž„αž™αž›αŸ‹αž”αž“αŸ’αžαŸ‚αž˜
αž€αŸαž˜αžΆαž“β€‹αž’αŸ’αž“αž€β€‹αžŸαŸ’αžœαŸ‚αž„αžšαž€β€‹αžŠαŸ‚αžš
αžŸαŸ’αžœαŸ‚αž„αžšαž€
αžŸαž˜αŸ’αž’αžΆαžβ€‹αž€αžΆαžšβ€‹αžŸαŸ’αžœαŸ‚αž„αžšαž€
αž”αž·αž‘β€‹αž€αžΆαžšβ€‹αžŸαŸ’αžœαŸ‚αž„αžšαž€
αž€αž˜αŸ’αž˜αžœαž·αž’αžΈ Google
αž˜αŸ‰αžΊαž“αž»αž™αžŠαžΎαž˜